Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.59 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.54 |
| ▸ | DRD2 | P14416 | 1/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.54 |
| ▸ | IDO1 | P14902 | 2/20 | 0.47 |
| ▸ | AGXT | P21549 | 2/20 | 0.47 |
| ▸ | DAO | P14920 | 1/20 | 0.44 |
| ▸ | MIF | P14174 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27821895 | 0.94 | TAAR1 (0.57) | TAAR1SLC6A3DRD2SLC6A4IDO1 | |
| SCHEMBL4469226 | 0.92 | TAAR1 (0.55) | TAAR1SLC6A3DRD2SLC6A4IDO1 | |
| SCHEMBL31035947 | 0.92 | TAAR1 (0.55) | TAAR1SLC6A3DRD2SLC6A4IDO1 | |
| SCHEMBL931383 | 0.87 | TAAR1 (0.63) | TAAR1SLC6A3DRD2SLC6A4IDO1 | |
| SCHEMBL30186558 | 0.87 | TAAR1 (0.63) | TAAR1SLC6A3DRD2SLC6A4IDO1 | |
| SCHEMBL4402199 | 0.84 | TDP1 (0.46) | TAAR1 | |
| SCHEMBL3371633 | 0.82 | TAAR1 (0.74) | TAAR1SLC6A3DRD2SLC6A4IDO1 | |
| SCHEMBL16038467 | 0.81 | TAAR1 (0.67) | TAAR1SLC6A3DRD2SLC6A4IDO1 | |
| SCHEMBL8727622 | 0.79 | TAAR1 (0.59) | TAAR1SLC6A3DRD2SLC6A4IDO1 | |
| SCHEMBL900638 | 0.79 | TAAR1 (0.59) | TAAR1SLC6A3DRD2SLC6A4IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110982024-A | Hydroxy benzene ring block emulsion polymer for nano powder and ATRP preparation method thereof | 湖北工业大学 | 2020-04-10 | — | — | CN | disclosed |
| EP-2168944-B1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2016-05-11 | — | — | EP | disclosed |
| EP-2168944-B1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2016-05-11 | — | — | EP | disclosed |
| CN-101730677-B | Amine compound and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORP | 2014-07-16 | — | — | CN | disclosed |
| US-8129361-B2 | Amine compound and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-03-06 | — | — | US | disclosed |
| US-8129361-B2 | Amine compound and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-03-06 | — | — | US | disclosed |
| US-8129361-B2 | Amine compound and pharmaceutical use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2012-03-06 | — | — | US | disclosed |
| US-20100179216-A1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-07-15 | — | — | US | disclosed |
| US-20100179216-A1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-07-15 | — | — | US | disclosed |
| US-20100179216-A1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2010-07-15 | — | — | US | disclosed |
| EP-2168944-A1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-03-31 | — | — | EP | disclosed |
| WO-2010011325-A2 | SYNTHESIS AND UTILIZATION OF SMALL MOLECULES FOR THE TREATMENT OF INFLAMMATION ASSOCIATED WITH INTERLEUKIN-1 SIGNALING | THE SCRIPPS RESEARCH INSTITUTE (US) | 2010-01-28 | — | — | WO | disclosed |
| US-7135466-B2 | Quinoline and quinazoline derivatives and drugs containing the same | KIRIN BEER KABUSHIKI KAISHA (JP) | 2006-11-14 | — | — | US | disclosed |
| US-20060211717-A1 | Quinoline and quinazoline derivatives and drugs containing the same | KIRIN BEER KABUSHIKI KAISHA (JP) | 2006-09-21 | — | — | US | disclosed |
| US-20040132727-A1 | Quinoline and quinazoline derivatives and drugs containing the same | KIRIN HOLDINGS KABUSHIKI KAISHA (JP) | 2004-07-08 | — | — | US | disclosed |
| CN-1374959-A | Piperidine quinolyl propyl derivatives, preparation method and compositions containing same | AVENTIS PHARMA SA (FR) | 2002-10-16 | — | — | CN | disclosed |
| EP-1243582-A1 | QUINOLINE AND QUINAZOLINE DERIVATIVES AND DRUGS CONTAINING THE SAME | KIRIN BEER KABUSHIKI KAISHA (JP) | 2002-09-25 | — | — | EP | disclosed |
| EP-1218370-A2 | QUINOLYL PROPYL PIPERIDINE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | Aventis Pharma S.A. (FR) | 2002-07-03 | — | — | EP | disclosed |
| US-6403610-B1 | ANTIMICROBIAL AGENTS | AVENTIS PHARMA S.A. (FR) | 2002-06-11 | — | — | US | disclosed |
| WO-2001025227-A2 | QUINOLYL PROPYL PIPERIDINE DERIVATIVES AND THEIR USE AS ANTIBACTERIAL AGENTS | AVENTIS PHARMA S.A. (FR) | 2001-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060211717-A1 | Quinoline and quinazoline derivatives and drugs containing the same | PDGFRA, PDGFRB, PDGFA | TAAR1 222/4885SLC6A3 771/4885DRD2 621/4885 |
| US-20040132727-A1 | Quinoline and quinazoline derivatives and drugs containing the same | PDGFRA, PDGFRB, PDGFA | TAAR1 327/4885SLC6A3 603/4885DRD2 747/4885 |
| US-20100179216-A1 | AMINE COMPOUND AND PHARMACEUTICAL USE THEREOF | HLA-B, HLA-A, HLA-C | TAAR1 197/4885SLC6A3 177/4885DRD2 649/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.